Antigen peptide transporters are upregulated in squamous cell carcinoma of the oral tongue and show sex-specific associations with survival.

immune evasion sex squamous cell carcinoma of the oral tongue tongue transporter associated with antigen processing 1 transporter associated with antigen processing 2

Journal

Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236

Informations de publication

Date de publication:
Nov 2022
Historique:
received: 04 08 2022
accepted: 30 08 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 25 10 2022
Statut: epublish

Résumé

Transporter associated with antigen processing 1 (TAP1) and TAP2 serve pivotal roles in adaptive immunity. Tumor cells often show reduced antigen presentation on their surface as one mechanism to escape immune recognition. Whether downregulation of TAPs is a common mechanism of tumor immune evasion in squamous cell carcinoma of the oral tongue (SCCOT) is unclear. In the present study, samples from 78 patients with SCCOT and 17 patients with benign hyperplastic tongue lesions were analyzed for TAP1 and TAP2 expression by immunohistochemistry. The percentage of positive cells and staining intensity were scored. Associations with clinicopathological variables and survival outcome were also investigated. The results demonstrated that TAP1 and TAP2 levels were highly associated with each other in individual samples and were upregulated in SCCOT compared with benign lesions (P<0.001). The proportion of TAP1- or TAP2-positive tumor cells was >80% in all but two of the tumors, whereas 25.6 and 23.0% of the tumors showed weak intensity of TAP1 and TAP2, respectively. There were no significant associations with clinicopathological variables or survival outcomes between TAP-intermediate/strong and TAP-weak tumors. However, in patients <70 years old and with early stage SCCOT, male patients had better outcomes than female patients (log-rank P<0.05), and the best outcome was observed in male patients with intermediate/strong TAP expression. In conclusion, loss of TAP was not a frequent event in SCCOT and stronger TAP expression in male patients was associated with improved survival, providing further evidence for sex-specific immune modulation in cancer.

Identifiants

pubmed: 36276482
doi: 10.3892/ol.2022.13510
pii: OL-24-05-13510
pmc: PMC9533359
doi:

Types de publication

Journal Article

Langues

eng

Pagination

390

Informations de copyright

Copyright: © Attaran et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

Clin Cancer Res. 2010 Oct 15;16(20):5019-27
pubmed: 20943762
Otolaryngol Head Neck Surg. 2008 Jun;138(6):768-71
pubmed: 18503852
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Head Face Med. 2017 May 10;13(1):6
pubmed: 28486965
Nat Rev Immunol. 2020 Nov;20(11):651-668
pubmed: 32433532
Mol Immunol. 2022 Feb;142:105-119
pubmed: 34973498
Cancer Discov. 2021 Feb;11(2):282-292
pubmed: 33127846
Front Immunol. 2022 Feb 28;13:844866
pubmed: 35296095
J Immunol. 1999 Oct 15;163(8):4224-31
pubmed: 10510359
Cancer Res. 2006 Sep 15;66(18):9281-9
pubmed: 16982773
Cancer Immunol Immunother. 2018 Jun;67(6):999-1009
pubmed: 29487978
Oncol Rep. 2010 Apr;23(4):933-9
pubmed: 20204276
Tissue Antigens. 1999 Sep;54(3):235-45
pubmed: 10519360
Nat Rev Cancer. 2021 May;21(5):298-312
pubmed: 33750922
Cancers (Basel). 2021 Oct 09;13(20):
pubmed: 34680201
J Clin Pathol. 1995 Sep;48(9):876-8
pubmed: 7490328
Clin Cancer Res. 2005 Apr 1;11(7):2552-60
pubmed: 15814633
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
Oral Oncol. 2021 Jan;112:105093
pubmed: 33232879
Immunol Res. 2005;33(2):113-33
pubmed: 16234579
Int J Mol Sci. 2020 Aug 27;21(17):
pubmed: 32867395
Nat Commun. 2020 Aug 17;11(1):4128
pubmed: 32807809
J Natl Cancer Inst. 2013 Aug 21;105(16):1172-87
pubmed: 23852952
Cell Syst. 2022 Feb 16;13(2):183-193.e7
pubmed: 34731645
Oral Oncol. 2011 Sep;47(9):861-5
pubmed: 21802344
Am J Surg Pathol. 2005 Feb;29(2):167-78
pubmed: 15644773
Cell. 2017 Nov 16;171(5):1029-1041.e21
pubmed: 29056346
Front Immunol. 2021 Mar 09;12:636568
pubmed: 33767702

Auteurs

Nima Attaran (N)

Department of Medical Biosciences/Pathology, Umeå University, Umeå 901 87, Sweden.

Philip J Coates (PJ)

Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic.

Katarina Zborayova (K)

Department of Clinical Sciences, Division of Ear, Nose and Throat Diseases, Umeå University, Umeå 901 87, Sweden.

Baris Erdogan (B)

Department of Clinical Sciences, Division of Ear, Nose and Throat Diseases, Umeå University, Umeå 901 87, Sweden.

Mustafa Magan (M)

Department of Clinical Sciences, Division of Ear, Nose and Throat Diseases, Umeå University, Umeå 901 87, Sweden.

Nicola Sgaramella (N)

Department of Medical Biosciences/Pathology, Umeå University, Umeå 901 87, Sweden.

Karin Nylander (K)

Department of Medical Biosciences/Pathology, Umeå University, Umeå 901 87, Sweden.

Xiaolian Gu (X)

Department of Medical Biosciences/Pathology, Umeå University, Umeå 901 87, Sweden.

Classifications MeSH